| __timestamp | Geron Corporation | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 15746000 |
| Thursday, January 1, 2015 | 17793000 | 13392000 |
| Friday, January 1, 2016 | 18761000 | 9290000 |
| Sunday, January 1, 2017 | 19287000 | 7672000 |
| Monday, January 1, 2018 | 18707000 | 15293000 |
| Tuesday, January 1, 2019 | 20893000 | 22648000 |
| Wednesday, January 1, 2020 | 25678000 | 21864000 |
| Friday, January 1, 2021 | 29665000 | 37318000 |
| Saturday, January 1, 2022 | 43628000 | 48130000 |
| Sunday, January 1, 2023 | 69135000 | 108146000 |
Unleashing insights
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Madrigal Pharmaceuticals, Inc. and Geron Corporation have demonstrated distinct spending patterns. From 2014 to 2023, Madrigal's SG&A expenses surged by approximately 587%, peaking at over $108 million in 2023. In contrast, Geron Corporation's SG&A expenses increased by about 313%, reaching nearly $69 million in the same year. This divergence highlights Madrigal's aggressive investment in administrative capabilities and market expansion, while Geron has maintained a more conservative approach. The data suggests that Madrigal's strategy may be aimed at rapid growth and market penetration, whereas Geron might be focusing on sustainable, steady development. These insights provide a fascinating glimpse into how two companies navigate the financial landscape of the biotech industry.
Cost Management Insights: SG&A Expenses for GSK plc and Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Geron Corporation
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation